Separately, Maxim Group reaffirmed a hold rating on shares of DelMar Pharmaceuticals in a research note on Monday, September 11th.
Shares of DelMar Pharmaceuticals (DMPI) traded up $0.23 during trading hours on Thursday, reaching $1.68. 2,863,424 shares of the company were exchanged, compared to its average volume of 1,441,961. The company has a market capitalization of $36.18, a PE ratio of -2.43 and a beta of 0.91. DelMar Pharmaceuticals has a fifty-two week low of $0.78 and a fifty-two week high of $5.39.
In related news, CEO Saiid Zarrabian bought 60,900 shares of the firm’s stock in a transaction on Tuesday, November 14th. The shares were purchased at an average price of $0.82 per share, with a total value of $49,938.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Several hedge funds and other institutional investors have recently bought and sold shares of DMPI. Franklin Resources Inc. bought a new stake in shares of DelMar Pharmaceuticals during the second quarter worth $2,477,000. Sabby Management LLC bought a new stake in shares of DelMar Pharmaceuticals during the second quarter worth $1,484,000. Finally, Susquehanna International Group LLP bought a new stake in shares of DelMar Pharmaceuticals during the third quarter worth $306,000. 16.91% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “DelMar Pharmaceuticals (DMPI) Given a $12.00 Price Target by HC Wainwright Analysts” was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.com-unik.info/2018/01/07/delmar-pharmaceuticals-dmpi-given-a-12-00-price-target-by-hc-wainwright-analysts.html.
About DelMar Pharmaceuticals
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
What are top analysts saying about DelMar Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DelMar Pharmaceuticals and related companies.